Cargando…

Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection

BACKGROUND: A novel treatment method is required for recalcitrant common warts. OBJECTIVE: This study aimed to compare the complete wart removal rate of cidofovir, a broad-spectrum antiviral agent, intralesional injection and sodium tetradecyl sulfate intralesional injection. METHODS: This retrospec...

Descripción completa

Detalles Bibliográficos
Autor principal: Oh, Byung Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992651/
https://www.ncbi.nlm.nih.gov/pubmed/33911754
http://dx.doi.org/10.5021/ad.2020.32.4.273
_version_ 1783669420282871808
author Oh, Byung Ho
author_facet Oh, Byung Ho
author_sort Oh, Byung Ho
collection PubMed
description BACKGROUND: A novel treatment method is required for recalcitrant common warts. OBJECTIVE: This study aimed to compare the complete wart removal rate of cidofovir, a broad-spectrum antiviral agent, intralesional injection and sodium tetradecyl sulfate intralesional injection. METHODS: This retrospective study included 45 patients with recalcitrant common warts on the hands and/or feet, treated with cidofovir or sodium tetradecyl sulfate intralesional injection. RESULTS: The treatment results were evaluated in three groups as follows: (1) failure - recalcitrant common warts remaining despite three or more injections, (2) success - free from warts for more than 6 months after the injection, and (3) recurrence. The cidofovir group (n=22) showed significantly higher treatment success rates than the sodium tetradecyl sulfate group (n=23) (90.91% vs. 26.09%, p<0.001). Two immunosuppressed patients in the cidofovir group had recurrent lesions after 2 months of being declared free from warts. Considering adverse effects, two patients in the cidofovir group complained of bulla formation with severe pain requiring narcotic painkillers. CONCLUSION: Although this study has the limitations of a small sample size and retrospective design, patients with recalcitrant common warts showed a dramatic response to the treatment with cidofovir intralesional injection, with minimal complications.
format Online
Article
Text
id pubmed-7992651
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Dermatological Association; The Korean Society for Investigative Dermatology
record_format MEDLINE/PubMed
spelling pubmed-79926512021-04-27 Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection Oh, Byung Ho Ann Dermatol Original Article BACKGROUND: A novel treatment method is required for recalcitrant common warts. OBJECTIVE: This study aimed to compare the complete wart removal rate of cidofovir, a broad-spectrum antiviral agent, intralesional injection and sodium tetradecyl sulfate intralesional injection. METHODS: This retrospective study included 45 patients with recalcitrant common warts on the hands and/or feet, treated with cidofovir or sodium tetradecyl sulfate intralesional injection. RESULTS: The treatment results were evaluated in three groups as follows: (1) failure - recalcitrant common warts remaining despite three or more injections, (2) success - free from warts for more than 6 months after the injection, and (3) recurrence. The cidofovir group (n=22) showed significantly higher treatment success rates than the sodium tetradecyl sulfate group (n=23) (90.91% vs. 26.09%, p<0.001). Two immunosuppressed patients in the cidofovir group had recurrent lesions after 2 months of being declared free from warts. Considering adverse effects, two patients in the cidofovir group complained of bulla formation with severe pain requiring narcotic painkillers. CONCLUSION: Although this study has the limitations of a small sample size and retrospective design, patients with recalcitrant common warts showed a dramatic response to the treatment with cidofovir intralesional injection, with minimal complications. The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2020-08 2020-06-30 /pmc/articles/PMC7992651/ /pubmed/33911754 http://dx.doi.org/10.5021/ad.2020.32.4.273 Text en Copyright © 2020 The Korean Dermatological Association and The Korean Society for Investigative Dermatology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Oh, Byung Ho
Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection
title Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection
title_full Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection
title_fullStr Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection
title_full_unstemmed Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection
title_short Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection
title_sort cidofovir intralesional injection for recalcitrant common warts: a comparison with sodium tetradecyl sulfate intralesional injection
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992651/
https://www.ncbi.nlm.nih.gov/pubmed/33911754
http://dx.doi.org/10.5021/ad.2020.32.4.273
work_keys_str_mv AT ohbyungho cidofovirintralesionalinjectionforrecalcitrantcommonwartsacomparisonwithsodiumtetradecylsulfateintralesionalinjection